康弘药业：依帕司他片获得药品注册证书

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Ipatasertib from the National Medical Products Administration, indicating a significant advancement in its product pipeline for treating diabetic neuropathy [1] Company Summary - Kanghong Pharmaceutical announced the receipt of the drug registration certificate for Ipatasertib, which is intended for the treatment of diabetic neuropathy [1]